Antimicrobial Agents and Chemotherapy · 2011 · 56 citations · 7 references
PharmacyPharmacologyPharmacotherapyAntimicrobial PharmacologyAntimicrobial PharmacotherapyClinical PharmacologyAntibacterial PharmacotherapyAntibacterial TherapyCombination Antimicrobial TherapyEmpiric Antimicrobial TherapyEmpiric Therapy SelectionHelicobacter Pylori Eradication TherapyEmpiric Eradication RegimensFirst-line Eradication TherapyHelicobacter Pylori EradicationHelicobacter Pylori InfectionMetronidazole TherapyMutationSecond-line Eradication Therapy
Sitafloxacin-based triple therapy achieved 83.6% (per-protocol) and 78.2% (intention-to-treat) success in eradicating Helicobacter pylori among 78 Japanese patients after clarithromycin-based first-line and metronidazole-based second-line triple therapies failed. Eradication succeeded in 32 out of 43 patients, even with gyrA mutation-positive Helicobacter pylori (per protocol). The position of the gyrA mutation (N87 or D91) was determined to be a better marker than MIC levels for predicting outcomes of sitafloxacin-based treatment.
7
Jyh‐Ming Liou, Chi‐Yang Chang, Wang‐Huei Sheng et al. · Antimicrobial Agents and Chemotherapy · 2010 · 69 citations
Toshihiro Nishizawa, Hidekazu Suzuki, Kumiko Kurabayashi et al. · Antimicrobial Agents and Chemotherapy · 2006 · 56 citations · Full text
Mutations of Helicobacter pylori Associated with Fluoroquinolone Resistance in Korea
Jung W. Lee, Nayoung Kim, Ryoung Hee Nam et al. · Helicobacter · 2011 · 49 citations